APLA12 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01123655 (ClinicalTrials.gov) | October 2009 | 12/5/2010 | Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients | Phase 1 Trial of CII APL A12 in Rheumatoid Arthritis Patients | Rheumatoid Arthritis | Drug: APLA12;Drug: Placebo | VA Office of Research and Development | NULL | Completed | 18 Years | 85 Years | All | 22 | Phase 1 | United States |